Table 1.
TCGA ovarian serous cystadenocarcinoma patient characteristics.
| Characteristic | Overall | |
| n | 376 | |
| OS event (%) | Alive | 146 (38.8) |
| Dead | 230 (61.2) | |
| FIGO stage (%) | Stage I | 1 (0.3) |
| Stage II | 22 (5.9) | |
| Stage III | 293 (78.6) | |
| Stage IV | 57 (15.3) | |
| Histologic grade (%) | G1 | 1 (0.3) |
| G2 | 42 (11.5) | |
| G3 | 322 (88.0) | |
| G4 | 1 (0.3) | |
| Tumor status (%) | Tumor free | 71 (21.3) |
| With tumor | 262 (78.7) | |
| Primary therapy outcome (%) | PD | 27 (8.9) |
| SD | 22 (7.2) | |
| PR | 43 (14.1) | |
| CR | 213 (69.8) | |
| Age (%) | <60 | 198 (52.7) |
| ≥60 | 178 (47.3) | |
| Residual tumor (%) | NRD | 66 (19.8) |
| RD | 267 (80.2) | |
| Lymphatic invasion (%) | NO | 48 (32.4) |
| YES | 100 (67.6) | |
| Venous invasion (%) | NO | 40 (38.8) |
| YES | 63 (61.2) | |
| Anatomic subdivision (%) | Unilateral | 101 (28.5) |
| Bilateral | 253 (71.5) |
CR = complete remission, NRD = no residual disease, OS = overall survival, PD = progressive Disease, PR = partial remission, RD = residual disease, SD = stable disease, TCGA = The Cancer Genome Atlas.